Needham & Company LLC reissued their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK – Get Rating) in a research report sent to investors on Tuesday, Benzinga reports. Needham & Company LLC currently has a $25.00 price objective on the stock.
Several other research firms have also recently weighed in on STOK. Bank of America cut shares of Stoke Therapeutics from a buy rating to an underperform rating and lowered their price target for the company from $22.00 to $9.00 in a report on Friday, January 6th. Credit Suisse Group lowered their price target on shares of Stoke Therapeutics from $32.00 to $28.00 and set an outperform rating on the stock in a report on Tuesday. Wedbush lowered their price target on shares of Stoke Therapeutics from $33.00 to $25.00 and set an outperform rating on the stock in a report on Tuesday. Cantor Fitzgerald reissued an overweight rating and issued a $20.00 price target on shares of Stoke Therapeutics in a report on Tuesday. Finally, HC Wainwright reissued a buy rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Tuesday. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus price target of $24.57.
Stoke Therapeutics Stock Performance
Shares of NASDAQ:STOK opened at $8.85 on Tuesday. Stoke Therapeutics has a 52-week low of $6.88 and a 52-week high of $26.60. The company has a market capitalization of $390.73 million, a P/E ratio of -3.40 and a beta of 0.42. The company has a 50-day simple moving average of $9.21 and a 200 day simple moving average of $10.94.
Insider Transactions at Stoke Therapeutics
In other news, insider Barry Ticho sold 9,235 shares of the firm’s stock in a transaction that occurred on Monday, February 6th. The shares were sold at an average price of $10.02, for a total transaction of $92,534.70. Following the transaction, the insider now directly owns 111,725 shares of the company’s stock, valued at $1,119,484.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders have sold 9,702 shares of company stock valued at $97,205. 12.70% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in STOK. Wellington Management Group LLP bought a new position in shares of Stoke Therapeutics during the first quarter worth approximately $25,011,000. Bank of Montreal Can bought a new position in Stoke Therapeutics in the second quarter valued at approximately $13,793,000. Millennium Management LLC increased its stake in Stoke Therapeutics by 121.9% in the second quarter. Millennium Management LLC now owns 949,658 shares of the company’s stock valued at $12,545,000 after acquiring an additional 521,661 shares during the last quarter. Deutsche Bank AG increased its stake in Stoke Therapeutics by 190.0% in the second quarter. Deutsche Bank AG now owns 788,381 shares of the company’s stock valued at $10,415,000 after acquiring an additional 516,495 shares during the last quarter. Finally, Norges Bank bought a new position in Stoke Therapeutics in the fourth quarter valued at approximately $3,640,000.
Stoke Therapeutics Company Profile
Stoke Therapeutics, Inc is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
- Get a free copy of the StockNews.com research report on Stoke Therapeutics (STOK)
- Fossil Group: Should You Bet On Consumer Discretionary In 2023?
- BJ’s Wholesale Club Stock Moves Higher After Strong Results
- Monthly Realty Income is About to Get Bigger
- 3 Large Cap Dividend Challengers for Millennial Investors
- Sea Ltd Is On The Verge Of A 100% Rally, Should You Buy?
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.